1 January 2026 in Canadian Journal of Infectious Diseases and Medical Microbiology
Background: The Outpatient Parenteral Antimicrobial Therapy (OPAT) Clinic at the Alberta Children’s Hospital (ACH) offers a vital service, enabling stable pediatric patients to receive intravenous (IV) antimicrobial therapy on an outpatient basis. Established in 1997, the program aims to reduce hospital admissions and enhance patient experience. Eligible patients with various infectious conditions receive initial treatment in the emergency department before transitioning to outpatient care. The program not only improves patient satisfaction but also minimizes the risks associated with hospital stays, such as hospital‐acquired infections, while addressing the challenges of antibiotic stewardship and monitoring for potential complications. This study seeks to characterize OPAT outcomes in pediatric patients, filling a gap in existing literature. Methods: We conducted a retrospective descriptive study reviewing records of patients under 18 years of age treated with IV antimicrobials as outpatients within the OPAT program. Data were collected from electronic hospital records from May 1, 2023, to May 31, 2024. All data entries were recorded in REDCap as our data management platform. Result: The study included 902 pediatric participants, with 455 males (50.4%); 32.9% were 1–5 years of age, followed by 26.9% of 6–10 years of age. The most common diagnoses were cellulitis (15.7%), genitourinary (GU) infections (15.5%), dental infections (9.8%), and pneumonia (8.2%). Ceftriaxone was the primary IV antibiotic for GU infections, while cefazolin was commonly used for cellulitis and dental infections. Of the total participants, 8% required hospitalization due to worsening infection or to increase the frequency of antibiotics. Additionally, a higher rate of admission was noted in males ( p = 0.03). Most patients (97%) received peripheral IV access with minimal complications. Overall, OPAT demonstrated high efficacy and safety in managing pediatric infections. Conclusion: This study underscores the safety of OPAT. Supported by a multidisciplinary team, the program effectively treated common infections primarily using ceftriaxone. Most patients maintained peripheral IV access without significant complications. While hospitalization rates were low, notable differences between male and female patients warrant further investigation into contributing factors to these disparities.
10 September 2026 in The Pediatric Infectious Disease Journal
FSfor Members of the Canadian Immunization Monitoring Program, Active (IMPACT) COVID-19 Study
for Members of the Canadian Immunization Monitoring Program, Active (IMPACT) COVID-19 Study
+11
Background: Co-circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with other respiratory viruses raised concerns that coinfections may increase pediatric coronavirus disease 2019 (COVID-19) severity, but evidence is limited by variable testing practices. We assessed the epidemiology and outcomes of SARS-CoV-2 respiratory viral coinfections in hospitalized children. Methods: We analyzed national surveillance data from the Canadian Immunization Monitoring Program, ACTive (IMPACT) COVID-19 study. Children aged <17 years hospitalized with confirmed COVID-19 during Delta and Omicron periods were included. Coinfection was defined as SARS-CoV-2 plus ≥1 additional respiratory virus. Primary analyses were restricted to centres with systematic multiplex polymerase chain reaction (PCR) testing of all admissions with acute respiratory illness (n = 5), while secondary analyses included all centres (n = 13). Associations with outcomes (respiratory support, ventilation, intensive care and severe COVID-19) were estimated using multivariable mixed-effects logistic regression and adjusted odds ratios (aORs). Results: Among 2831 hospitalized children, 938 were admitted at centers with systematic multiplex PCR testing, among whom 18.6% had ≥1 respiratory viral coinfection. Respiratory syncytial virus (39.7%) and enterovirus/rhinovirus (38.5%) coinfections were the most common. Coinfections were not associated with increased odds of severe COVID-19 in centers with systematic multiplex PCR testing (aOR 0.94; 95% confidence interval, 0.76–1.15). In secondary analyses including all centers irrespective of testing strategy, coinfections were associated with increased odds of severe COVID-19 (aOR 1.42; 95% confidence interval, 1.05–1.91). Conclusions: In centers that systematically conducted multiplex PCR testing, SARS-CoV-2 respiratory viral coinfections were not associated with increased COVID-19 severity. Differences observed when including centers without systematic testing underscore the importance of considering testing strategies when evaluating the clinical impact of coinfections.